Format

Send to

Choose Destination
See comment in PubMed Commons below
Sci Rep. 2014 Jun 4;4:5128. doi: 10.1038/srep05128.

Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity.

Author information

1
1] Department of Biomedical Engineering, Duke University, USA [2] Department of Chemical & Biomolecular Engineering, National University of Singapore, Singapore.
2
Department of Pathology, Duke University Medical Center, USA.
3
1] Department of Biomedical Engineering, Duke University, USA [2] Department of Surgery, Duke University Medical Center, USA.
4
Department of Surgery, Duke University Medical Center, USA.

Abstract

Direct in vivo administration of messenger RNA (mRNA) delivered in both naked and nanoparticle formats are actively investigated because the use of dendritic cells transfected ex vivo with mRNA for cancer therapy is expensive and needs significant infrastructure. Notably, intravenous and subcutaneous injections are the only routes of administration tested for mRNA nanoparticle tumor vaccination. In this report, we demonstrate that tumor immunity can be achieved via nasal administration of mRNA. Mice nasally immunized with mRNA delivered in nanoparticle format demonstrate delayed tumor progression in both prophylactic and therapeutic immunization models. The observed tumor immunity correlates with splenic antigen-specific CD8+ T cells and is achieved only when mRNA is delivered in nanoparticle but not in naked format. In conclusion, we demonstrate, as a proof-of-concept, a non-invasive approach to mRNA tumor vaccination, increasing its potential as a broadly applicable and off-the-shelf therapy for cancer treatment.

PMID:
24894817
PMCID:
PMC4044635
DOI:
10.1038/srep05128
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center